title: Evaluation of lung function and deposition of aerosolized bronchodilators carried by heliox associated with positive expiratory pressure in stable asthmatics: a randomized clinical trial.
abstract: While administration of medical aerosols with heliox and positive airway pressure are both used clinically to improve aerosol delivery, few studies have differentiated their separate roles in treatment of asthmatics. The aim of this randomized, double blinded study is to differentiate the effect of heliox and oxygen with and without positive expiratory pressure (PEP), on delivery of radiotagged inhaled bronchodilators on pulmonary function and deposition in asthmatics. 32 patients between 18 and 65 years of age diagnosed with stable moderate to severe asthma were randomly assigned into four groups: (1) Heliox + PEP (n = 6), (2) Oxygen + PEP (n = 6), (3) Heliox (n = 11) and (4) Oxygen without PEP (n = 9). Each group received 1 mg of fenoterol and 2 mg of ipratropium bromide combined with 25 mCi (955 Mbq) of Technetium-99m and 0.9% saline to a total dose volume of 3 mL placed in a Venticis II nebulizer attached to a closed, valved mask with PEP of 0 or 10 cm H2O. Both gas type and PEP level were blinded to the investigators. Images were acquired with a single-head scintillation camera with the longitudinal and transverse division of the right lung as regions of interest (ROIs). While all groups responded to bronchodilators, only group 1 showed increase in FEV1%predicted and IC compared to the other groups (p < 0.04). When evaluating the ROI in the vertical gradient we observed higher deposition in the middle and lower third in groups 1 (p = 0.02) and 2 (p = 0.01) compared to group 3. In the horizontal gradient, a higher deposition in the central region in groups 1 (p = 0.03) and 2 (p = 0.02) compared to group 3 and intermediate region of group 2 compared to group 3. We conclude that aerosol deposition was higher in groups with PEP independent of gas used, while bronchodilator response with Heliox + PEP improved FEV1 % and IC compared to administration with Oxygen, Oxygen with PEP and Heliox alone. Trial registration NCT01268462.
authors.affiliation: Department of Physiotherapy, Universidade Federal de Pernambuco, Recife, Brazil.
authors.forename: Luciana
authors.initials: L
authors.lastname: Alcoforado
authors.forename: Simone
authors.initials: S
authors.lastname: Brandão
authors.forename: Catarina
authors.initials: C
authors.lastname: Rattes
authors.forename: Daniella
authors.initials: D
authors.lastname: Brandão
authors.forename: Vitória
authors.initials: V
authors.lastname: Lima
authors.forename: Gildo
authors.initials: G
authors.lastname: Ferreira Lima
authors.forename: James B
authors.initials: JB
authors.lastname: Fink
authors.forename: Armele
authors.initials: A
authors.lastname: Dornelas de Andrade
mesh_terms: D000293:Adolescent; D000328:Adult; D000336:Aerosols / Q000008:administration & dosage; D000368:Aged; D000704:Analysis of Variance; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000378:metabolism; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000378:metabolism; D004337:Drug Carriers / Q000008:administration & dosage; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006371:Helium / Q000008:administration & dosage; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage* / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D010100:Oxygen / Q000008:administration & dosage; D011175:Positive-Pressure Respiration; D019275:Radiopharmaceuticals; D016284:Technetium Tc 99m Pentetate; D014797:Vital Capacity / Q000187:drug effects; D055815:Young Adult
chemical_list: D000336:Aerosols; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D004337:Drug Carriers; D019275:Radiopharmaceuticals; D006371:Helium; C038949:heliox; D009241:Ipratropium; D010100:Oxygen; D016284:Technetium Tc 99m Pentetate
keywords: Aerosol; Asthma; COPD; CPAP; DBP; DTPA – Tc(99m); EPAP; FEV(1); FVC; HR; Helium; IC; IPPB; PEEP; PEEPi; PEF; PEP; ROIs; RR; SBP; SpO(2); chronic obstructive pulmonary disease; continuous positive airway pressure; diastolic blood pressure; diethylenetriaminepentaacetic acid technetium-99m; expiratory positive airway pressure; forced expiratory volume in the first second; forced vital capacity; heart rate; inspiratory capacity; intermittent positive pressure breathing; intrinsic positive end expiratory pressure; peak expiratory flow; peripheral oxygen saturation; positive end expiratory pressure; positive expiratory pressure; regions of interest; respiratory rate; systolic blood pressure